Business
Physiomics to provide cardiac toxicity modelling
Physiomics to provide cardiac toxicity modelling.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 7155A Physiomics PLC 25 March 2013 \n 25 March 2013\n\nPhysiomics plc \n(the \"Company\" or \"Physiomics\") \nPhysiomics to provide cardiac toxicity modelling service \nPhysiomics plc (AIM: PYC), the Oxford, UK-based systems biology company, is pleased to announce the launch of its new cardiac toxicity modelling service. This new model predicts the risk of a fatal heart arrhythmia known as Torsade de Pointes, using low cost and relatively easy to obtain lab-based data. From 1990 to 2010, a dozen compounds were withdrawn from the market because of association with Torsade de Pointes. \n It is understood that the current industry standard tool to predict cardiac toxicity risk is only partially predictive. The Physiomics method aims to reduce the number of candidates incorrectly rejected and also to reduce the number of compounds incorrectly advanced into costly clinical trials. The directors believe it is significantly better than the available published models at predicting cardiac toxicity side effects.\n Further information on this cardiac toxicity platform can be found on the Physiomics plc website.\n Dr Mark Chadwick, CEO of Physiomics, commented: \"This new model fits well with our overall strategy of reducing the risk, timelines and costs associated with drug discovery and development. Applicable across all therapeutic areas, it should provide access to a broader range of customers worldwide.\"\n Enquiries:\n Physiomics plc \nMark Chadwick \n+44 (0)1865 784980\nWH Ireland Limited\nKaty Mitchell\n+44 (0) 161 832 2174\n \nAbout Physiomics plc\nPhysiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 mi...